Dako, an Agilent Technologies company, announced positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx. The Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer. Dako introduced the cutting- edge IQFISH hybridization buffer chemistry in 2012. The IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours. As an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor. The French study found that Instant Quality, or IQ, FISH provides "excellent quality signals without any background staining, thus allowing excellent reading conditions." The study also points out "almost perfect agreement between IQFISH and FISH" and that IQFISH is a "safe, reliable and fast method that is easy to use in routine practice" with few reruns. The statement is significant in that the tissue came from five different laboratories using four different fixation methods. The study concludes that the highly concordant results and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status. It also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.